Comparable stake leader
PAVmed Inc.
SEC ownership of Lucid Diagnostics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001799011.
Disclosed value leader
PAVmed Inc.
Comparable rows
50/50
Latest evidence
20 May 2026
- Public ticker
- LUCD on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PAVmed Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PAVmed Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
20 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001799011
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Lucid Diagnostics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PAVmed Inc.
Disclosed value leader
PAVmed Inc.
Comparable rows
50/50
Latest evidence
20 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 28%
13D/G row: PAVmed Inc.
Showing 1-8 of 50 holder rows.
Quick read
PAVmed Inc. leads the comparable SEC ownership view at 28%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PAVmed Inc.'s linked filing trail.
Comparable ownership
Top 5
PAVmed Inc.
28%
Ayrton Capital LLC
2%
Aklog Lishan
2.6%
Dennis M. Mcgrath
1.3%
Shaun O'Neil
1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PAVmed Inc. |
13D/G
3/4/5
10%+ Owner
|
28%
|
$46,192,115
38,816,903 shares
|
$0 | 03 Feb 2026 |
| Ayrton Capital LLC |
13D/G
|
2%
|
$1,596,645
1,200,485 shares
|
$0 | 31 Dec 2024 |
| Aklog Lishan |
3/4/5
Chief Executive Officer, Director
|
2.6%
|
$4,145,754
3,636,627 shares
|
— | 20 Feb 2026 |
| Dennis M. Mcgrath |
3/4/5
Chief Financial Officer
|
1.3%
|
$2,067,468
1,813,569 shares
|
— | 20 Feb 2026 |
| Shaun O'Neil |
3/4/5
President and COO
|
1%
|
$1,649,309
1,446,763 shares
|
— | 20 Feb 2026 |
| Dennis Matheis |
3/4/5
Director
|
0.73%
|
$1,034,579
1,033,443 shares
|
+$347,110 | 20 May 2026 |
| Michael A. Gordon |
3/4/5
General Counsel and Secretary
|
0.71%
|
$1,140,000
1,000,000 shares
|
— | 20 Feb 2026 |
| Victoria Tou-Ho Lee |
3/4/5
Chief Medical Officer
|
0.46%
|
$747,500
650,000 shares
|
— | 23 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$347,110.
Buys
$347,110
Insiders: 1
Sells
$0
Insiders: 0
Net
+$347,110
Shares: +345,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 345,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 245,000 | 0 | $245,270 | $0 | +$245,270 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 100,000 | 0 | $101,840 | $0 | +$101,840 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Lucid Diagnostics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
PAVmed Inc.
Net 12M change
+$347,110
Latest report
20 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| PAVmed Inc. | 10%+ Owner | $43,926,720 | Mixed | 15 Feb 2024 | ||
| Aklog Lishan | Chief Executive Officer, Director | $4,145,754 | Mixed | 20 Feb 2026 | ||
| Dennis M. Mcgrath | Chief Financial Officer | $2,067,468 | Mixed | 20 Feb 2026 | ||
| Shaun O'Neil | President and COO | $1,649,309 | Mixed | 20 Feb 2026 | ||
| Michael A. Gordon | General Counsel and Secretary | $1,140,000 | Mixed | 20 Feb 2026 | ||
| Dennis Matheis | Director | $1,034,579 | +$347,110 | +50% | Filing P/S | 20 May 2026 |
| Victoria Tou-Ho Lee | Chief Medical Officer | $747,500 | Mixed | 23 Mar 2026 | ||
| James L. Cox | Director | $461,836 | Mixed | 20 Feb 2026 | ||
| John R. Palumbo | Director | $385,320 | Mixed | 20 Feb 2026 | ||
| Stanley Lapidus | Director | $384,626 | Mixed | 20 Feb 2026 | ||
| Ronald M. Sparks | Director | $365,324 | Mixed | 20 Feb 2026 | ||
| Jacque J. Sokolov | Director | $365,324 | Mixed | 20 Feb 2026 | ||
| Debra White | Director | $268,812 | Mixed | 20 Feb 2026 | ||
| Aster Angagaw | Director | Mixed | 18 Feb 2022 | |||
| David F. Wurtman | Chief Medical Officer | Mixed | 13 Oct 2021 |
Recent insider transactions for Lucid Diagnostics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Dennis Matheis | LUCD | Common Stock | Purchase | 31.1% | $245,270 | $1.00 | 245,000 | 1,033,443 | 20 May 2026 | Direct |
| Lishan Aklog | LUCD | Common Stock | Award | 148% | 2,170,000 | 3,636,627 | 20 Feb 2026 | Direct | ||
| Dennis Matheis | LUCD | Common Stock | Award | 18.5% | 123,000 | 788,443 | 20 Feb 2026 | Direct | ||
| Debra White | LUCD | Common Stock | Award | 109% | 123,000 | 235,800 | 20 Feb 2026 | Direct | ||
| Ronald M. Sparks | LUCD | Common stock | Award | 62.3% | 123,000 | 320,460 | 20 Feb 2026 | Direct | ||
| Jacque J. Sokolov | LUCD | Common Stock | Award | 62.3% | 123,000 | 320,460 | 20 Feb 2026 | Direct | ||
| John R. Palumbo | LUCD | Common Stock | Award | 57.2% | 123,000 | 338,000 | 20 Feb 2026 | Direct | ||
| Stanley Lapidus | LUCD | Common Stock | Award | 57.4% | 123,000 | 337,392 | 20 Feb 2026 | Direct | ||
| James L. Cox | LUCD | Common Stock | Award | 43.6% | 123,000 | 405,120 | 20 Feb 2026 | Direct | ||
| Dennis M. Mcgrath | LUCD | Common stock | Award | 35% | 470,000 | 1,813,569 | 20 Feb 2026 | Direct | ||
| Shaun O'Neil | LUCD | Common stock | Award | 75% | 620,000 | 1,446,763 | 20 Feb 2026 | Direct | ||
| Michael A. Gordon | LUCD | Common stock | Award | 42.9% | 300,000 | 1,000,000 | 20 Feb 2026 | Direct | ||
| John R. Palumbo | LUCD | Employee stock option (right to buy) | Award | 215,000 | 215,000 | 06 Oct 2025 | Direct | |||
| Dennis Matheis | LUCD | Common Stock | Purchase | 17.7% | $101,840 | $1.02 | 100,000 | 665,443 | 20 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.